Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$23.32
-$0.35(-1.79%)
At close: 4:00 PM EST
$23.32
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.24M
Market Cap
$2.85B
Enterprise Value$2.16B
Total Cash (Recent Filing)$709.17M
Total Debt (Recent Filing)$2.79M
Price to Earnings (P/E)13.3
Beta0.65
Next Earnings
May 13, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding122,123,886
10 Day Avg. Volume1,202,762
30 Day Avg. Volume1,244,457
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)2.99
Price to Sales (P/S)4.85
P/FCF Ratio13.68
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.30
Enterprise Value/Ebitda6.90
Forecast
1Y Price Target
$34.50Price Target Upside47.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.84
Revenue Forecast (FY)$629.83M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumStrong Agamree launch dynamics, high payer approval rates, streamlined fulfillment and a favorable side effect profile are driving new patient starts and improving retention, supporting sustained commercial growth.
Patent LitigationA favorable resolution of the remaining patent challenge for Firdapse would strengthen the brand's market exclusivity and could support higher sales and share-price appreciation.
Royalty And Margin ImprovementScheduled reductions in upstream royalty obligations should materially improve reported revenues and margins, helping to offset increased selling expenses while maintaining cash flexibility.
Bears Say
Clinical Development RiskA finding of immunosuppressive effects in the ongoing study could limit Agamree's label expansion and prevent entry into broader markets that depend on long-term steroid alternatives.
Generic CompetitionSignificant generic competition for Fycompa and the discontinuation of promotional support are eroding that product's sales contribution and weakening overall revenue diversification.
Reimbursement PressureIncreasing Medicare Part D-related gross-to-net pressures are likely to create headwinds for reported revenue and compress net sales across the portfolio.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.85B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is May 13, 2026 which is in 50 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Feb 26, 2026. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.344 by $0.066.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.45.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,123,886 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.41 in its last earnings report, beating expectations of $0.344. Following the earnings report the stock price went down -7.235%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Catalyst Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (47.94% Upside)
$34.50 (47.94% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 236.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.59%
12-Months-Change
Fundamentals
Return on Equity
24.32%
Trailing 12-Months
Asset Growth
29.53%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$34.50
▲(47.94% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
5.59% Insiders
18.22% Mutual Funds
19.00% Other Institutional Investors
29.55% Public Companies and Individual Investors